There is accumulating evidence that the increase in CVD burden is present in patients prior to dialysis, due to both conventional risk factors as well as those specific to kidney disease.[3]

Atherosclerosis begins many years before the development of clinical manifestations.[4,5] Studies have shown that hemodialysis patients have advanced changes in the walls of their arteries, which can present as increased intima-media thickness (IMT) in the carotid and femoral arteries.[6,7] The pathophysiological mechanisms of atherosclerosis in CKD patients are not yet fully established. However, it is known that in addition to the traditional risk factors described in the Framingham Heart Study, other factors related to uremia such as hyperphosphatemia and hyperparathyroidism play a role in the development of the disease in this population.[8-10]

Carotid intima-media thickness (CIMT) has been reported as representative of subclinical and asymptomatic
atherosclerotic vascular diseases and therefore CIMT is a procedure to detect early atherosclerotic changes. The visualized lesion in the common carotid artery (CCA) has been reported to correlate to the degree of atherosclerotic lesions elsewhere in the body. Hence, the measurement of the IMT by ultrasonography of the carotid artery is been presently recommended for cardiovascular risk assessment. CIMT is a self-determining predictor of coronary heart disease after adjustment of the other risk factors for CVDs. Some studies have indicated CIMT as a predictor of cardiovascular events in patients undergoing hemodialysis. The study was conducted to establish a correlation between CIMT and cardiovascular risk factors and to investigate its prognostic significance in CKD patients on hemodialysis.

Materials and Methods

After Ethical Clearance from Institutional Ethic Committee, this prospective study was carried out in Department of Medicine, K.G. Medical University, Lucknow, Uttar Pradesh, India during August 2013-January 2015.

Study population

Patients with CKD stage-V, age between 18 and 65 years, who were on maintenance hemodialysis for at least 6 months in the nephrology unit, fulfilling the inclusion criteria of the study and provided written consent for participation were included in the study as per Kidney Disease Improving Global Outcomes guidelines 2012. Age and gender matched 50 healthy control were also enrolled in the study. Patients suffering with septicemic acute renal failure, history of CVD, malignancy, hypothyroidism, inflammatory disorder, and those subjects who are not willing to take part in the study were excluded from the study.

Clinical evaluation

The estimated glomerular filtration rate of <60 mL/min/1.73 m² for 3 months was defined as CKD. CKD stage-V defined as estimated glomerular filtration rate of <15 mL/min/1.73 m². Modification of diet in renal disease formula was used to calculate the estimated glomerular filtration rate. Hypertension was defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg. Obesity was defined as body mass index (BMI) >25 kg/m² (as opposed to 30 kg/m² at the international level) and hyperlipidemia was defined as plasma cholesterol levels ≥240 mg/dL or plasma low-density lipoprotein (LDL) levels ≥160 mg/dL or plasma triglyceride levels ≥150 mg/dL electrocardiogram (ECG) was recorded just before the starting of dialysis. The presence of abnormal Q or inverted T wave in extremity leads was defined as ischemic ECG changes.

All the patients had been subjected to regular hemodialysis for 4 h 3 times a week at a blood flow rate of 180-220 mL/min using bicarbonate dialysate (30 mEq/L) at a flow rate of 500 mL/min. Usage of polysulfone dialyzer membranes: Low-flux ultrafiltration rate (UFR) (20 mL/min), medium-flux UFR (20-40 mL/min), and high-flux UFR (40 mL/min) was included in hemodialysis. The dialyzer membrane was not reused in any of patients, neither bacteria nor pyrogen was detected in the dialysate prepared from water obtained by reverse osmosis.

Biochemical assay

Five milliliter of venous blood sample was withdrawn with full aseptic precaution after an overnight fast from both cases and controls. The blood was centrifuged at 5000 rpm for 10 min at room temperature, serum was separated for routine hematology, biochemistry, urinalysis, and urine protein measurements were performed. An automated blood-cell analyzer (BC-5380, Mindray, China) was used for routine hematology testing, and an automated clinical biochemistry analyzer (Cobas C 311, Roche-Hitachi, Japan) was used to measure blood urea, serum creatinine, serum uric acid, serum lipids, serum electrolytes, and albumin. Corrected calcium was calculated by using formula: Corrected calcium = 0.8 (4-serum albumin) + serum calcium (mg/dL).

Carotid ultrasound

Carotid Doppler ultrasonography was performed by a single operator expert ultrasonologist and CIMT was measured in the Department of Radiology; the operator was blinded about the history and laboratory findings of the patients. The CIMT was defined as a hypo-echogenic space between two echogenic lines containing intima-media interface and media-adventitia interface on the posterior wall of the carotid artery. For performing carotid Doppler ultrasonography, the patient was asked to lie down on the examination table in the supine position. His/her neck was rotated in a superior and leftward direction, so that the right carotid artery was exposed. Following this, using a 7.5 MHz linear array transducer with high-resolution B-mode ultrasonography system (GE LOGIQ TOSHIBA XAIRO, Japan) the length and site of bifurcation of CCA was determined, posterior wall was exposed, and CIMT was measured. This device can measure the thickness by 0.1 mm.

Follow-up study

After the determination of initial laboratory and atherogenic parameters, all the patients were followed up for 18 months. No patient was lost to follow-up. All the patients were follow-up by a nephrologist for at least
3 months. Each death was reviewed and assigned an underlying cause by three physicians. Cardiovascular outcome measure was recorded as stroke, acute myocardial infarction, and congestive heart failure. We divided all subjects into either expired and nonexpired groups and evaluated the influence of CIMT on the outcome.

**Statistical analysis**
Continuous variable are expressed as mean ± standard deviation and compared using one-way ANOVA in case of normally distributed data and Kruskal-Wallis test for nonnormal data. Categorical variable was compared using Chi-square test. Correlations between various kidney function parameters have been calculated using Pearson or Spearman correlation coefficient. Pearson’s correlation coefficient was used to calculate the correlation between CIMT and other demographic and biochemical parameters. Regression analysis was carried out using CIMT as the dependent variable and other demographic and biochemical parameters as the independent variables. Receiver operator curve analysis has been done to calculate the area under the curve (AUC) for CIMT and identifying the optimal CIMT cut-off values for predicting mortality. Survival between the two groups was compared by the Kaplan-Meier method. Adjusted risk estimates for mortality were calculated using univariate and multivariate Cox proportional hazard regression models. Statistical significance was set at $P < 0.05$. All the analysis has been done using STATICA version 13 and MedCalc software (MedCalc Software bvba, Acacialaan 22 8400 Ostend Belgium).

**Results**

**Characteristic of study subject**
Of 88 CKD stage-V patients, 47 were male and 41 were female, and in 50 normal healthy controls, 27 (54.0%) were male, and 23 (46.0%) were female. Among these patients, 82% were taking angiotensin-converting enzyme inhibitors, 77% were on diuretics, 42% were on beta blockers and 42% were taking calcium channel blockers. The use of statins was observed in 34% of the patients, 32% were taking sevelamer, 5% were on calcitriol, and 5% were taking calcium carbonate. The aforementioned drugs were maintained during the follow-up period.

Mean age was 40.22 ± 12.31 years in controls, 39.54 ± 12.49 years in nonexpired group and 44.55 ± 15.11 in expired group ($P = 0.85$). Mean BMI was higher in controls in comparison to case ($P < 0.001$). Both systolic and diastolic blood pressure were higher in cases in comparison with control ($P < 0.001$). Estimated glomerular filtration rate was normal in control subject whereas markedly decreased in cases ($P < 0.001$). During the study, 88 patients received dialysis, two patients underwent renal transplantation, and 29 were expired in this period. There were 34 cardiovascular events like angina ($n = 14$), stroke ($n = 2$), acute myocardial infarction ($n = 13$), hypertensive emergency ($n = 2$), arrhythmia ($n = 1$), transient ischemic attack ($n = 1$), and heart failure ($n = 1$). The deaths were attributed due to acute myocardial infarction, congestive heart failure, and stroke. Mean CIMT was higher in expired group (1.02 ± 0.21) than in nonexpired group (0.92 ± 0.12) and (0.55 ± 0.06) in controls ($P < 0.001$) [Table 1].

Mean value of creatinine, calcium, serum phosphorus, serum calcium-phosphorus product and 24 h urine protein were higher in expired and nonexpired group in comparison to healthy control group. This difference was statistically significant ($P < 0.01$, $P < 0.001$) [Table 2].

**Correlation of carotid intima-media thickness with cardiovascular risk factors**
Correlation of CIMT with different variables was analyzed in controls and hemodialysis group. Significant positive correlation was found with age ($r = 0.327$, $P < 0.001$), blood urea ($r = 0.423$, $P < 0.001$), serum

| Table 1: Demographic profile of the study subjects |
|--------------------------------------------------|
| **Parameters**                    | **Control (n = 50)** (mean ± SD) | **Nonexpired (n = 59)** (mean ± SD) | **Expired (n = 29)** (mean ± SD) | **P** |
| ---                               | ---                            | ---                               | ---                             | ---   |
| Gender                            | ---                            | ---                               | ---                             | ---   |
| Male                              | 27 (54.0)                      | 32 (54.24)                        | 15 (51.72)                      | 0.973 |
| Female                            | 23 (46.0)                      | 27 (45.76)                        | 64 (46.38)                      |       |
| Age (years)                       | 40.22±12.31                    | 39.54±12.49                       | 44.55±15.11                     | 0.85  |
| BMI (kg/m²)                       | 22.59±1.71                     | 19.5±1.97                         | 19.1±1.88                      | <0.001|
| SBP (mmHg)                        | 120.72±7.79                    | 164.98±11.66                      | 165.79±12.22                   | <0.001|
| DBP (mmHg)                        | 64.6±5.86                      | 93.8±8.11                         | 94.4±8.13                      | <0.001|
| eGFR (mL/min)                     | 114.17±20.57                   | 9.30±2.89                         | 7.17±3.22                      | <0.001|
| CIMT (mm)                         | 0.55±0.06                      | 0.92±0.12                         | 1.02±0.21                      | <0.001|

SBP = Systolic blood pressure, BMI = Body mass index, DBP = Diastolic blood pressure, CIMT = Carotid intima-media thickness, eGFR = Estimated glomerular filtration rate, SD = Standard deviation
creatinine \( (r = 0.684, P < 0.001) \), serum triglyceride \( (r = 0.397, P < 0.001) \), high-density lipoprotein (HDL) \( (r = 0.389, P < 0.01) \), total cholesterol \( (r = 0.463, P < 0.01) \), LDL \( (r = 0.324, P < 0.001) \), corrected calcium \( (r = 0.383, P < 0.001) \), serum phosphorus \( (r = 0.482, P < 0.001) \), serum calcium phosphorus product \( (r = 0.364, P < 0.001) \), serum Mg\(^{2+}\) \( (r = 0.362, P < 0.001) \), serum uric acid \( (r = 0.383, P < 0.001) \), 24 h urine protein \( (r = 0.268, P < 0.001) \), systolic blood pressure \( (r = 0.342, P < 0.001) \), diastolic blood pressure \( (r = 0.343, P < 0.001) \), and BMI \( (r = 0.374, P < 0.001) \). Negative correlation was found with estimated glomerular filtration rate \( (r = -0.15, P < 0.001) \) [Table 3].

Regression analysis performed using CIMT as the dependent variable in a multiple regression model including covariate reported in univariate analysis. The associations with age \( (\beta = 0.34, P < 0.01) \), albumin \( (\beta = 0.35, P < 0.01) \) and serum calcium phosphorus product \( (\beta = 0.32, P < 0.01) \) were found to be statistically significant in the analysis [Table 4].

### Impact of carotid intima-media thickness

Univariate cox proportional regression analysis revealed that various factors such as age, the product of calcium and phosphorus, albumin, and CIMT were associated with all-cause mortality. Multivariate regression analysis demonstrated that albumin and CIMT became significant independent predictors of all-cause mortality. Adjusted hazards ratios of all cause and cardiovascular mortality for an increase of 0.1 mm in CIMT was 1.16 (95% confidence interval [CI]: 1.05-1.28) [Table 5]. 0.1 mm increment of CIMT also increased the risk of cardiovascular mortality by 16% (95% CI: 0.15-0.37) in patients who have otherwise no history of any cardiovascular events [Tables 5 and 6]. The AUC for CIMT was 0.725 (95% CI: 0.619-0.815). A CIMT cut-off of 0.97 had a sensitivity of 88.97% and specificity of 72.88% in predicting the mortality. The +likelihood ratio (LR) value of 2.54 (95% CI 1.6-4.1) and -LR value of 0.43 (95% CI 0.2-0.7) [Figure 1].

Kaplan-Meier survival curve shows CIMT to be closely associated with the renal end point in CKDs patient. Based on the cut-off value of CIMT at 0.97 mm, patients with value <0.97 mm had a renal survival rate of 73.4% while patients with greater than cut-off value of CIMT had a renal survival rate of 16.5% [Figure 2].

### Table 2: Biochemical profile of the study subjects

| Parameters              | Control \( (n = 50) \) (mean ± SD) | Nonexpired \( (n = 59) \) (mean ± SD) | Expired \( (n = 29) \) (mean ± SD) | \( P \) |
|-------------------------|----------------------------------|--------------------------------------|----------------------------------|------|
| Serum creatinine \( (mg%) \) | 0.78±0.18                        | 6.95±1.85                           | 8.96±3.62                        | <0.001 |
| Serum calcium++ \( (mg%) \)  | 8.44±0.69                        | 7.29±1.19                           | 7.28±1.52                        | <0.01  |
| Serum phosphorus \( (mg%) \) | 2.96±0.46                        | 8.95±3.15                           | 9.19±2.90                        | <0.001 |
| Serum calcium × serum phosphorus | 25.0±4.58                      | 63.08±20.65                         | 68.46±29.03                      | <0.05  |
| Hemoglobin \( (g%) \)    | 11.36±2.21                       | 7.55±1.66                           | 7.85±2.24                        | <0.001 |
| LDL \( (mg%) \)          | 69.09±58.36                      | 116.27±64.13                        | 111.79±30.39                     | <0.001 |
| HDL \( (mg%) \)          | 41.24±7.79                       | 36.17±10.34                         | 32.81±10.02                      | <0.01  |
| TG \( (mg%) \)           | 92.42±19.93                      | 151.65±112.24                      | 149.88±39.79                     | <0.01  |
| TC \( (mg%) \)           | 168.05±52.11                     | 163.96±69.80                       | 165.48±53.14                     | <0.01  |
| Serum albumin \( (mg%) \) | 4.25±0.28                        | 3.30±0.42                           | 3.35±0.56                        | <0.001 |
| 24 h urine protein \( (mg%) \) | 135.12±21.07                 | 1850.41±2346.61                     | 1908.10±1344.04                  | <0.001 |
| Serum uric acid \( (mg%) \) | 5.77±0.98                       | 9.35±3.06                           | 10.16±1.92                       | <0.001 |

LDL = Low-density lipoprotein, HDL = High-density lipoprotein, TG = Triglyceride, TC = Total cholesterol, SD = Standard deviation

### Table 3: Correlation of CIMT with different variables in control group \( (n = 50) \) and hemodialysis group \( (n = 88) \)

| Parameters              | Control group | Hemodialysis group |
|-------------------------|---------------|-------------------|
|                        | \( r \) | \( P \) | \( r \) | \( P \) |
| Age                    | 0.33 | 0.054 | 0.327 | <0.001 |
| GFR                    | -0.15 | 0.688 | -0.15 | 0.001 |
| Serum urea             | -0.13 | 0.730 | 0.423 | <0.001 |
| Serum creatinine       | 0.17 | 0.343 | 0.684 | <0.001 |
| Serum TG               | 0.15 | 0.331 | 0.397 | <0.001 |
| HDL                    | 0.13 | 0.298 | 0.389 | <0.01  |
| LDL                    | -0.21 | 0.212 | 0.324 | 0.001 |
| TC                     | -0.13 | 0.320 | 0.463 | <0.01  |
| Corrected calcium      | 0.01 | 0.483 | 0.383 | <0.001 |
| Serum phosphorus       | 0.23 | 0.432 | 0.482 | <0.0010 |
| Serum calcium phosphorus product | 0.23 | 0.353 | 0.364 | <0.0010 |
| Serum magnesium        | 0.24 | 0.504 | 0.362 | <0.001 |
| Serum uric acid        | -0.13 | 0.727 | 0.383 | <0.001 |
| 24 h urine protein      | -0.17 | 0.647 | 0.268 | <0.001 |
| Serum albumin          | 0.21 | 0.567 | 0.20  | <0.01  |
| SBP                    | 0.09 | 0.799 | 0.342 | <0.001 |
| DBP                    | -0.29 | 0.411 | 0.343 | <0.001 |
| BMI                    | 0.13 | 0.718 | 0.374 | <0.001 |

CIMT = Carotid intima-media thickness, BMI = Body mass index, GFR = Glomerular filtration rate, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, TG = Triglyceride, LDL = Low-density lipoprotein, HDL = High-density lipoprotein, TC = Total cholesterol
Hemodialysis patients are highly prone to CVD, which accounts for roughly half of the mortality in these patients. Atherosclerosis is the most common cause of cardiovascular morbidity in ESRD patients. In healthy middle-aged adults, CIMT values between 0.6 and 0.7 mm have been considered normal, while CIMT of 1 mm or more has been associated with significant risk of coronary heart diseases.[18] In healthy Indian adults, the average and maximum CIMT values reported were 0.67 and 0.70 mm, respectively.[19] The measurement of CIMT varies with age and values >1.0 mm are considered abnormal in younger population and confer increased absolute risk of coronary heart disease.[20,21] In our study, mean value of CIMT in expired group was higher (1.02 ± 0.21 mm) as compared to nonexpired group on hemodialysis (0.92 ± 0.12 mm). This showed that expired group was much prone to atherosclerosis in comparison with nonexpired group.

Recently, increased CIMT is reported as an independent predictor of cardiovascular events and mortality in

### Discussion

**Table 4: Multiple regression analysis of CIMT (expiry and nonexpiry subjects)**

| Parameter                  | β coeff. | P       |
|----------------------------|----------|---------|
| Age                        | 0.34     | <0.01   |
| SBP                        | -0.16    | 0.14    |
| DBP                        | 0.17     | 0.12    |
| eGFR                       | -0.18    | 0.58    |
| Serum uric acid            | 0.05     | 0.68    |
| 24 h urine protein         | -0.12    | 0.28    |
| Serum albumin              | 0.35     | <0.01   |
| Serum calcium++            | 0.11     | 0.31    |
| Serum phosphorus           | 0.12     | 0.26    |
| Serum calcium × serum phosphorus | 0.32  | <0.01   |
| TG                         | -0.10    | 0.35    |
| LDL                        | -0.02    | 0.83    |
| HDL                        | -0.01    | 0.93    |
| Blood urea                 | 0.08     | 0.44    |
| Serum creatinine           | 0.28     | 0.52    |

β is the standardized coefficient, SBP = Systolic blood pressure, DBP = Diastolic blood pressure, eGFR = Estimated glomerular filtration rate, SD = Standard deviation, TG = Triglyceride, LDL = Low density lipoprotein, HDL = High density lipoprotein, CIMT = Carotid intima-media thickness

**Table 5: Univariate cox proportional hazard model**

| Parameter                  | Units of increase | HR      | 95% CI       |
|----------------------------|-------------------|---------|--------------|
| Age (years)                | 1                 | 1.03    | 1.003-1.06   |
| Calcium × phosphorus (mg²/dL²) | 1                 | 1.008   | 0.99-1.022   |
| Albumin (mg%) (g/dL)       | 1                 | 1.02    | 0.56-2.65    |
| CIMT (mm)                  | 0.1               | 1.17    | 0.16-9.56    |

HR = Hazard ratio, CI = Confidence interval, CIMT = Carotid intima-media thickness

**Table 6: Multivariate cox proportional hazard model**

| Parameter                  | Units of increase | HR      | 95% CI       |
|----------------------------|-------------------|---------|--------------|
| Age (years)                | 1                 | 1.004   | 0.98-1.03    |
| Calcium × phosphorus (mg²/dL²) | 1                 | 1.001   | 0.99-1.01    |
| Albumin (mg%) (g/dL)       | 1                 | 1.06    | 0.56-2.01    |
| CIMT (mm)                  | 0.1               | 1.16    | 0.15-9.09    |

HR = Hazard ratio, CI = Confidence interval, CIMT = Carotid intima-media thickness

**Figure 1:** Receiver operator curve for carotid intima-media thickness (CIMT) considering mortality as a status variable. The area under curve for CIMT was 0.725 (95% confidence interval [CI]: 0.619-0.815), A CIMT cut-off of 0.97 (unit required) had a sensitivity of 88.97% and specificity of 72.88% in predicting the mortality. The +likelihood ratio (LR) value of 2.54 (95% CI 1.6-4.1) and -LR value of 0.43 (95% CI 0.2-0.7)

**Figure 2:** Kaplan-Meier survival curve shows carotid intima-media thickness (CIMT) to be closely associated with the renal end point in chronic kidney disease patients. Based on the cut-off value of CIMT at of 0.97mm, patients with value <0.97 mm had a renal survival rate of 73.4% while patients with CIMT greater than cut-off value of CIMT had a renal survival rate of 16.5%.
Our study result showed that a mean CIMT of 0.92 ± 0.12 mm in a group of alive hemodialysis patients, which was significantly higher than in an age- and sex-matched control group, but in expired hemodialysis patients mean CIMT was still higher 1.02 ± 0.21 mm than alive hemodialysis patients. These results are in accordance with other authors.\cite{24,25} Increased carotid artery IMT is considered as a marker of early atherosclerotic changes.\cite{26} As per several studies, known traditional risk factors such as increasing age, hypercholesterolemia, hypertension, deranged fasting blood sugar, and smoking were also implicated as a risk factor for atherosclerosis in CKD.\cite{27}

In our study, 0.1 mm increment of CIMT also increased the risk of cardiovascular mortality by 16% (95% CI 0.15-9.09) in patients without a prior history of cardiovascular events. With compatible to our study Benedetto et al.\cite{14} first demonstrated that a 0.1 mm increment of CIMT predicted a 24% higher risk for cardiovascular mortality in end-stage renal failure patients on hemodialysis or peritoneal dialysis during a follow-up period of 30 months. Recently, Nishizawa et al.\cite{15} reported that increased CIMT became an independent predictor of 30-month cardiovascular death.

Atherosclerotic changes in carotid arteries are assumed to be indicative of atherosclerosis throughout the body and peripheral arteries.\cite{14,22,23} We also found that expired subjects had an increased CIMT in nondiabetics or nonsmoking patients, and associated with poor prognosis in nondiabetic subjects. These findings convincingly suggested that assessment of CIMT is useful in predicting future mortality in uremic patients.

Our study showed a significant correlation between CIMT and age ($r = 0.327$, $P < 0.001$), which is in concordance with other studies and indicates the natural progression of atherosclerosis with increasing age. Increasing trend of CIMT with age has been also reported by other authors.\cite{28,29}

Our study result showed the positive correlation between CIMT and other risk factors such as systolic and diastolic blood pressure, LDL and HDL levels, blood urea, serum creatinine, serum calcium, serum phosphorus, and serum uric acid. Our result were compatible with a study done by Briese et al.\cite{30} There was a trend for higher CIMT value in an expired group than nonexpired group dialysis patients. These findings emphasized the relationship between traditional cardiovascular risk factors and CIMT, which have been shown to be a predictor of CVD in many studies done previously.

In our study, however, univariate regression analysis failed to show any significant association between CIMT and mortality, but in multiple regression model including covariate reported using univariate analysis. The associations with age ($\beta = 0.34$, $P < 0.01$), serum albumin ($\beta = 0.35$, $P < 0.01$), and serum calcium-phosphorus product ($\beta = 0.32$, $P < 0.01$) were found to be statistically significant in the analysis. These finding was compatible with a study done by Kato et al.\cite{16} Kaplan-Meier survival curve shows CIMT to be closely associated with the renal end point in CKD patients. Based on the cut-off value of CIMT at of 0.97 mm, patients with value <0.97 mm had a renal survival rate of 73.4% while patients with greater than cut-off value of CIMT had a renal survival rate of 16.5%. In our study, cardiovascular mortality was 32.9%. Study done by other authors showed that a 0.1 mm increment of CIMT was associated with increased risk of cardiovascular mortality by 39% (95% CI, 1.11-1.75) in patients without a previous history of cardiovascular accidents.\cite{16}

Although it is clear that CIMT is a good predictor of subsequent mortality in hemodialysis patients. There are some limitations in our study:

1. Premature atherosclerosis, serum homocysteine, lipoprotein (a), obesity, physical activity, atherogenic diet, proinflammatory factors, and prothrombotic factors could not be included due to the limitations of budget and study design.
2. Small number of participants.

**Conclusion**

Various risk factors have been correlated to CIMT value in different studies, with some conflicting results. In the present study, we found a significant relationship between CIMT and serum calcium, phosphorus. Among the various described risk factors, we found a significant relationship between CIMT with age and serum cholesterol level. Therefore, it seems that the traditional risk factors for CVD in the normal population also affect the value of CIMT in dialysis and that uremia is an additive risk factor in those subjects who had raised CIMT. Thus, we propose cohort studies in different group of CKD patients on hemodialysis and form convincing association between CIMT and cardiovascular risk.

**References**

1. US Renal Data System. 2002 Annual Data Report, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD; 2002.
2. Locatelli F, Marcelli D, Conte F, D’Amico M, Del Vecchio L, Limido A, et al. Cardiovascular disease in chronic renal failure: The challenge continues. Registro Lombardo Dialisi e Trapianto. Nephrol Dial Transplant 2000;15 Suppl 5:69-80.
3. Levin A. Clinical epidemiology of cardiovascular disease in chronic kidney disease prior to dialysis. Semin Dial 2003;16:1-9.
4. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697-701.
5. Ross R. The pathogenesis of atherosclerosis. N Engl J Med 1993;329:807-10.
6. Kawagishi T, Nishizawa Y, Konishi T, et al. High resolution B-mode ultra sonography in evaluation of atherosclerosis. N Engl J Med 1974;290:697-701.
7. Shoji T, Kawagishi T, Emoto M, Maekawa K, Taniwaki H, Kanda H, et al. Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 2000;155:257-8.
8. Dawber TR. The Framingham Study: The Epidemiologic of Atherosclerotic Disease. Cambridge: Harvard University Press; 1980.
9. Falaknaz K, Tajbakhsh R, Sheikhholeslami FH, Taziki O, Bagheri N, Fasahi F, et al. Evaluation of association between intima-media thickness of the carotid artery and risk factors for cardiovascular disease in patients on maintenance hemodialysis. Saudi J Kidney Dis Transpl 2012;23:51-6.
10. Lemos MM, Watanabe R, Carvalho AB, Jancikic AD, Sanches FM, Christofalo DM, et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: A pilot study. Clin Nephrol 2013;80:1-8.
11. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010;122:e584-636.
12. Munter P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: Results from the atherosclerosis risk in communities study. J Am Soc Nephrol 2005;16:529-38.
13. Kieltyka L, Urbina EM, Tang R, Bond MG, Srinivasan SR, Berenson GS. Framingham risk score is related to carotid artery intima-media thickness in both white and black young adults: The Bogalusa Heart Study. Atherosclerosis 2003;170:125-30.
14. Benedetto FA, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001;12:2458-64.
15. Nishizawa Y, Shoji T, Maekawa K, Nagasue K, Okuno S, Kim M, et al. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2003;41:S76-9.
16. Kato A, Takita T, Maruyama Y, Kumagai H, Hishida A. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. Kidney Int 2003;64:1472-9.
17. Ekart R, Hojs R, Hojs-Fabjan T, Balon BP. Predictive value of carotid intima media thickness in hemodialysis patients. Artif Organs 2005;29:615-9.
18. Jacoby DS, Mohler 3rd ER, Rader DJ. Noninvasive atherosclerosis imaging for predicting cardiovascular events and assessing therapeutic interventions. Curr Atheroscler Rep 2004;6:20-6.
19. Hansa G, Bhargava K, Bansal M, Tandon S, Kasliwal RR. Carotid intima-media thickness and coronary artery disease: An Indian perspective. Asian Cardiovasc Thorac Ann 2003;11:217-21.
20. Ballantyne CM. Clinical Lipidology: A Companion to Braunwald’s Heart Diseases. 1st ed. Saunders Elsevier Publication; 2008. p. 608. (Accessed March 4, 2015, at http://www.amazon.com/Clinical-Lipidology-Companion-Braunwalds-Disease/dp/1416054693#reader_1416054693).
21. O’Leary DH, Bots ML. Imaging of atherosclerosis: Carotid intima-media thickness. Eur Heart J 2010;31:1682-9.
22. Burke GL, Evans GW, Riley WA, Sharrett AR, Howard G, Barnes RW, et al. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995;26:386-91.
23. Allan PL, Mowbray PI, Lee AJ, Fowkes FG. Relationship between carotid intima-media thickness and symptomatic and asymptomatic peripheral arterial disease. The Edinburgh Artery Study. Stroke 1997;28:348-53.
24. Kawagishi T, Nishizawa Y, Konishi T, Kawasuki K, Emoto M, Shoji T, et al. High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 1995;48:820-6.
25. Brzosko S, Lebkovska U, Malyszko J, Hrysztok T, Krauze-Brzosko K, Mysliwiec M. Intima media thickness of common carotid arteries is associated with traditional risk factors and presence of ischaemic heart disease in hemodialysis patients. Physiol Res 2005;54:497-504.
26. Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994;236:567-73.
27. Shlipak MG, Fried LF, Cushnner M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA 2005;293:1737-45.
28. Stein JH, Douglas PS, Srinivasan SR, Bond MG, Tang R, Li S, et al. Distribution and cross-sectional age-related increases of carotid artery intima-media thickness in young adults: The Bogalusa Heart Study. Stroke 2004;35:2782-7.
29. Bots ML, Evans GW, Riley WA, Grobbee DE. Carotid intima-media thickness measurements in intervention studies: Design options, progression rates, and sample size considerations: A point of view. Stroke 2003;34:2985-94.
30. Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, Sachan R, Kamal R. Impact of carotid intima-media thickness on long-term outcome in hemodialysis patients. North Am J Med Sci 2015;7:281-7.

Source of Support: Nil. Conflict of Interest: None declared.

How to cite this article: Patel ML, Radheyslyham, Verma A, Sachan R, Kamal R. Impact of carotid intima-media thickness on long-term outcome in hemodialysis patients. North Am J Med Sci 2015;7:281-7.